Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?
about
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancerCell-free circulating tumor DNA in cancerCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerTechnologies for Single-Cell IsolationWhole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Liquid biopsy genotyping in lung cancer: ready for clinical utility?eTumorType, An Algorithm of Discriminating Cancer Types for Circulating Tumor Cells or Cell-free DNAs in Blood.Circulating Tumor DNA as Biomarkers for Cancer Detection.Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer.Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patientsDiagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.Enumeration and molecular characterization of circulating tumor cell using an in vivo capture system in squamous cell carcinoma of head and neck.DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer.DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB)Detection of circulating tumor cells in non-small cell lung cancer.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples.Liquid Biopsies for Cancer: Coming to a Patient near You.Using the New CellCollector to Capture Circulating Tumor Cells from Blood in Different Groups of Pulmonary Disease: A Cohort Study.ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.Clinical and biological significance of circulating tumor cells in cancer.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Pathologists and liquid biopsies: to be or not to be?Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.Circulating tumor cells and microemboli can differentiate malignant and benign pulmonary lesions.Liquid biopsy? A recent breakthrough in noninvasive bladder cancer surveillance.Pros: Can tissue biopsy be replaced by liquid biopsy?Limitations in the Use of Serum Epidermal Growth Factor Receptor Mutations as Prognostic Markers for Non-Small-Cell Lung Cancer.Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period.Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France.Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
P2860
Q26746010-E3F498FF-AB5A-4C24-9145-D9B7931D115FQ26750899-1C8CB701-F2D7-4201-873E-086B8CC61195Q26775376-B20A84DB-E68F-4750-9797-597C5B07099AQ26799345-EF4828D2-6A44-4509-B302-D90E7A56567FQ27853196-343FFF2C-BB99-4C42-84E8-13FBF366C8DDQ28076191-A0CED041-7593-4BC2-90C5-AABC6A7262B3Q28077340-01C900B2-2B00-4FA5-8D94-AC2DEC213F4AQ33567037-58B60F04-EB54-4C8B-87FA-AECAA8464A28Q33631634-FE71AAE3-66B0-4CBF-B4EF-02D49E911631Q33632125-2753209E-B14B-48A9-B06E-42D09563DF46Q33684887-D63390BF-3BBD-4495-A523-418CA29F1089Q33688558-88B97801-3FC1-43AC-81A4-A27C2789033AQ33829668-121E5050-1029-4E99-8A35-0DCDECE01C18Q33871888-2F7D4212-2557-46F7-910D-0E6010654546Q36073749-11062D75-AE22-4EC8-A10B-1B00C9C35D91Q36101421-24BCC16D-9F4B-40BB-8271-24AEAAC120C5Q36370872-74293BC4-301B-4DF9-88AB-CBD9CCA5C870Q36430821-8487C27F-0B2D-4426-AD29-15BF9E14F16AQ36948886-73E6F7DD-51B5-42D4-9912-024AC25B5A7DQ37051546-34669793-FCA3-476C-A103-F31B36E00B12Q37317218-284115E3-504B-4B3B-9BC3-7F940431760CQ37628173-16C6459B-F092-481D-A2DA-B93EEA085E92Q38607644-9512E2ED-7991-4C31-94FD-8BDD1ADB7D22Q38626147-1833DFF6-3D88-46DF-97D8-5F7A882031A8Q38743200-A2AC5D9C-73C6-4E37-BB27-862337096EA9Q38844281-FD2D0C60-4813-4315-9FEA-3BE85C5F0047Q38935060-D8BD35CA-85E9-432B-A387-527EE18598DDQ39002233-9552FCC3-EFA1-40E0-82B1-F6E2B1C16388Q39294398-DCFCC0D0-BA58-442B-9D4C-F31D9F60BE21Q40482740-0A21F483-DB8B-4E49-989F-DB14CADC360AQ41440995-9762FB8E-F967-455B-BDAC-6C80B9F251F9Q42396536-DC31CC9D-9E25-4220-99BB-A1EF92E3E101Q42398704-773DC42C-9213-488A-9553-5DEE985D26A2Q42756564-01CC64FB-B10D-4BDA-A35B-D65801B5ABE6Q46110442-904EA93E-1320-4334-9BBF-259C6EF651DBQ46137433-14095A47-6475-47B9-9F1E-CD0A9DD36E69Q47153925-6CD16A81-F1DE-4A11-8286-37A2F87BC64BQ47184322-C5501F8A-23D8-4F40-97B5-0D72A7745FABQ49296229-07EC7939-4636-4A14-B87A-4181FFDEF146Q49787333-F4C10A22-D034-4DA0-8A18-918F929C8398
P2860
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Current challenges for detecti ...... ate for personalized medicine?
@ast
Current challenges for detecti ...... ate for personalized medicine?
@en
Current challenges for detecti ...... ate for personalized medicine?
@nl
type
label
Current challenges for detecti ...... ate for personalized medicine?
@ast
Current challenges for detecti ...... ate for personalized medicine?
@en
Current challenges for detecti ...... ate for personalized medicine?
@nl
prefLabel
Current challenges for detecti ...... ate for personalized medicine?
@ast
Current challenges for detecti ...... ate for personalized medicine?
@en
Current challenges for detecti ...... ate for personalized medicine?
@nl
P2093
P2860
P1476
Current challenges for detecti ...... ate for personalized medicine?
@en
P2093
Charles Hugo Marquette
Elodie Long
Eric Selva
Kevin Washetine
Marius Ilie
Olivier Bordone
Paul Hofman
Véronique Hofman
P2860
P356
10.3978/J.ISSN.2305-5839.2014.08.11
P577
2014-11-01T00:00:00Z